118 related articles for article (PubMed ID: 37926881)
1. Systemic Inflammatory Index: A Novel Biomarker for Predicting the Progression in Active Surveillance in Patients with Prostate Cancer.
Ozcan L; Omur M; Polat EC; Baran C; Boylu A; Otunctemur A
J Coll Physicians Surg Pak; 2023 Nov; 33(11):1278-1282. PubMed ID: 37926881
[TBL] [Abstract][Full Text] [Related]
2. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
3. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
4. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
5. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
[TBL] [Abstract][Full Text] [Related]
6. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
7. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.
Basourakos SP; Davis JW; Chapin BF; Ward JF; Pettaway CA; Pisters LL; Navai N; Achim MF; Wang X; Chen HC; Choi S; Kuban D; Troncoso P; Hanash S; Thompson TC; Kim J
BJU Int; 2018 Jan; 121(1):69-76. PubMed ID: 28710901
[TBL] [Abstract][Full Text] [Related]
8. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
Coen JJ; Feldman AS; Smith MR; Zietman AL
BJU Int; 2011 May; 107(10):1582-6. PubMed ID: 20860650
[TBL] [Abstract][Full Text] [Related]
9. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
10. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
11. A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up.
Song SH; Kim JK; Lee H; Lee S; Hong SK; Byun SS
Investig Clin Urol; 2021 Jan; 62(1):32-38. PubMed ID: 33258324
[TBL] [Abstract][Full Text] [Related]
12. Role of inflammatory factors in prediction of Gleason score and its upgrading in localized prostate cancer patients after radical prostatectomy.
Wang S; Ji Y; Ma J; Du P; Cao Y; Yang X; Yu Z; Yang Y
Front Oncol; 2022; 12():1079622. PubMed ID: 36713540
[TBL] [Abstract][Full Text] [Related]
13. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
14. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
[TBL] [Abstract][Full Text] [Related]
15. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
16. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
Thomsen FB
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
[TBL] [Abstract][Full Text] [Related]
20. How can we predict the active surveillance candidates meeting all Epstein criteria prior to prostate biopsy to avoid overdiagnosis?
Avci S; Caglayan V
Aging Male; 2020 Dec; 23(5):1289-1295. PubMed ID: 32406325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]